Author:
Saad Fred,De Porre Peter,Brookman-May Sabine,Li Jinhui,McCarthy Sharon A,Rathkopf Dana E
Reference7 articles.
1. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study;Saad;Lancet Oncol,2021
2. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results;Morris;J Clin Oncol,2015
3. Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: the PREVAIL randomized clinical trial;Rathkopf;JAMA Oncol,2018
4. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer;Sonpavde;BJU Int,2014
5. Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer;Maeda;Cancer Rep (Hoboken),2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献